Skip to content

The effect of Melissa officinalis on Female sexual desire

Assessment of effect of Product of Melissa officinalis on improvement of 18-50 years old Female sexual desire

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014021516580N1
Enrollment
38
Registered
2014-06-27
Start date
2014-07-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

female sexual dysfunction. Sexual dysfunction, not caused by organic disorder or disease

Interventions

Intervention 1: Intervention group, capsule contained 500 mg lemon balm extract, 2 times a day, every time 2 capsules after breakfast, dinner used for 4 weeks. Intervention 2: Control group, capsule c
Treatment - Drugs
Intervention group, capsule contained 500 mg lemon balm extract, 2 times a day, every time 2 capsules after breakfast, dinner used for 4 weeks.
Control group, capsule contained 500 mg starch , 2 times a day, every time 2 capsules after breakfast, dinner used for 4 weeks.

Sponsors

Vice chancellor for research of Shahed University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Women ages 18-50 years; Diagnosis low sexual desire by using the FSFI ( Female Sexual Function Index ); Emotionally satisfying relationship with constant wife sexually active at least one year; Having sex at least once a month; Lack of pregnancy and lactation; No menstruation retard for 2 months and more ; Normal genital examination. Exclusion criteria : Impaired emotionally satisfying relationship with wife ; Adding another partner in the study period; Any organic disease, anatomical and hormonal that exist in history and past medical history, including : diabetes , cerebrovascular disease , liver and kidney damage , heart disease , hypothyroidism, cancer; Psychiatric disorders who are under medical treatment; Smoking , alcohol , drug abuse; Use of any chemical and herbal medications that affect sexual desire.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Sexual desire. Timepoint: Baseline, 4 and 8 weeks after starting the medication. Method of measurement: Questionnaire Female Sexual Function Index.

Secondary

MeasureTime frame
Sexual arousal. Timepoint: Baseline, 4 and 8 weeks after starting the medication. Method of measurement: Questionnaire Female Sexual Function Index.;Sexual Satisfaction. Timepoint: Baseline, 4 and 8 weeks after starting the medication. Method of measurement: Questionnaire Female Sexual Function Index.;Obvious distress caused by sexual dysfunction. Timepoint: Baseline, 4 and 8 weeks after starting the medication. Method of measurement: Question of patients.;Painful intercourse. Timepoint: Baseline, 4 and 8 weeks after starting the medication. Method of measurement: Questionnaire Female Sexual Function Index.;Moisture of genitalia. Timepoint: Baseline, 4 and 8 weeks after starting the medication. Method of measurement: Questionnaire Female Sexual Function Index.;Increased frequency of sexual intercourse. Timepoint: Baseline, 4 and 8 weeks after starting the medication. Method of measurement: Question of patients.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Darvish Mofrad Kashani

Shahed University of Medical Sciences

z.kashani@shahed.ac.ir; zahrakashani14@yahoo.com+98 21 5567 8943

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026